quetiapine sold brand name seroquel among others atypical antipsychotic medication used treatment schizophrenia bipolar disorder major depressive despite widely used sleep aid due sedating effect benefits use appear generally outweigh side taken common side effects include sleepiness constipation weight gain dry side effects include low blood pressure standing seizures prolonged erection high blood sugar tardive dyskinesia neuroleptic malignant older people dementia use increases risk use third trimester pregnancy may result movement disorder baby time quetiapine believed work blocking number receptors including serotonin quetiapine developed approved medical use united states available generic commonly prescribed medication united states million world health organizations list essential quetiapine primarily used treat schizophrenia bipolar quetiapine targets positive secondary negative symptoms cochrane review compared quetiapine typical antipsychotics comparison antipsychotics effectiveness treating schizophrenia quetiapine demonstrated standard effectiveness effective ziprasidone chlorpromazine asenapine approximately effective haloperidol tentative evidence benefit quetiapine versus placebo schizophrenia however definitive conclusions possible due high rate attrition trials greater lack data economic outcomes social functioning quality debatable whether class typical atypical antipsychotics equal dropout symptom relapse rates typicals used low moderate quetiapine lower rates extrapyramidal side effects greater sleepiness rates dry cochrane review comparing quetiapine atypical antipsychotic agents tentatively concluded may less efficacious olanzapine risperidone produce fewer movement related side effects paliperidone aripiprazole ziprasidone risperidone olanzapine produce weight gain similar risperidone clozapine aripiprazole concluded produces suicide attempt suicide death qtc prolongation low blood pressure tachycardia sedation gynaecomastia galactorrhoea menstrual irregularity white blood cell count rate similar first generation bipolar disorder quetiapine used treat depressive episodes acute manic episodes associated bipolar disorder either monotherapy adjunct therapy lithium valproate lamotrigine acute mixed episodes maintenance treatment bipolar disorder adjunct therapy lithium divalproex quetiapine effective used used along medications major depressive disorder however sedation often undesirable side united united australia subsidised australian pharmaceutical benefits scheme treatment mdd quetiapine licensed use addon treatment quetiapine decrease agitation among people alzheimers disease quetiapine worsens intellectual functioning elderly dementia therefore use low doses quetiapine insomnia common recommended little evidence benefit concerns regarding adverse network metaanalysis doubleblind randomized controlled trials drug therapies vs placebo insomnia adults found quetiapine demonstrate shortterm benefits sleep quality quetiapine specifically effect size standardized mean difference placebo treatment insomnia citooltip confidence interval weeks treatment certainty evidence rated doses quetiapine used insomnia ranged mg low doses mg regardless dose used serious adverse effects may still possibly occur lower dosing ranges dyslipidemia safety concerns low doses corroborated danish observational studies showed use specifically lowdose quetiapine prescriptions filled tablet strengths mg excluded associated increased risk major cardiovascular events compared use zdrugs risk driven cardiovascular laboratory data unpublished analysis cohort also support lack dosedependency metabolic side effects new use lowdose quetiapine associated risk increased fasting triglycerides sometimes used offlabel often augmentation agent treat conditions tourette musical anxiety quetiapine clozapine widely used medications treatment parkinsons disease psychosis due low extrapyramidal sideeffect liabilitycitation needed owing risks associated clozapine eg agranulocytosis diabetes mellitus etc clinicians often attempt treatment quetiapine first although evidence support quetiapines use indication significantly weaker sources incidence typical atypical antipsychotics cause tardive according one study rates lower atypicals opposed typicals although quetiapine clozapine atypical antipsychotics switching atypicals option minimize symptoms tardive dyskinesia caused weight gain problem quetiapine causing weight gain fluphenazine haloperidol loxapine molindone olanzapine pimozide risperidone thioridazine thiothixene trifluoperazine ziprasidone less chlorpromazine clozapine perphenazine antipsychotics quetiapine may lower seizure taken caution combination drugs bupropion british national formulary recommends gradual withdrawal discontinuing antipsychotics avoid acute withdrawal syndrome rapid symptoms withdrawal commonly include nausea vomiting loss symptoms may include restlessness increased sweating trouble less commonly may feeling world spinning numbness muscle symptoms generally resolve short period tentative evidence discontinuation antipsychotics result may also result reoccurrence condition rarely tardive dyskinesia occur medication placental exposure least quetiapine compared atypical evidence insufficient rule risk foetus available data suggests unlikely result major foetal secreted breast milk hence quetiapinetreated mothers advised contrast antipsychotic drugs tend somewhat aversive often show problems patient compliance prescribed medication regimes quetiapine sometimes associated drug misuse abuse potential hypnotic sedative effects limited potential misuse usually individuals history polysubstance abuse andor mental illness especially incarcerated prisons secure psychiatric facilities access alternative intoxicants limited significantly greater extent atypical antipsychotic drugs quetiapine found associated drugseeking behaviors standardised street prices slang terms associated either combination drugs qball intravenous injection quetiapine mixed cocaine pharmacological basis distinction second generation antipsychotic drugs unclear though suggested quetiapines comparatively lower dopamine receptor affinity strong antihistamine activity might mean could regarded similar sedating antihistamines context issues regarded sufficient cause placing quetiapine increased legal controls prescribers urged show caution prescribing quetiapine individuals characteristics might place increased risk drug instances acute overdosage result sedation hypotension tachycardia cardiac arrhythmia coma death occurred adults serum plasma quetiapine concentrations usually mgl range overdose survivors postmortem blood levels mgl generally observed fatal nontoxic levels postmortem blood extend around mgkg toxic levels postmortem blood begin quetiapine following pharmacological means quetiapine dopamine serotonin adrenergic antagonist potent antihistamine anticholinergic quetiapine binds strongly serotonin receptors drug acts partial agonist serial pet scans evaluating receptor occupancy quetiapine demonstrated quetiapine rapidly disassociates theoretically allows normal physiological surges dopamine elicit normal effects areas nigrostriatal tuberoinfundibular pathways thus minimizing risk sideeffects pseudoparkinsonism well elevations antagonized receptors serotonin norepinephrine actually autoreceptors whose blockade tends increase release neurotransmitters low doses quetiapine acts primarily histamine receptor blocker antihistamine blocker dose increased quetiapine activates adrenergic system binds strongly serotonin receptors autoreceptors high doses quetiapine starts blocking significant amounts dopamine due drugs sedating activity often prescribed low doses insomnia feel low doses drugs antihistamine effects like quetiapine mirtazapine safer drugs associated physical dependency risk factors concern raised professionals offlabel prescribing become widespread due underappreciated treating schizophrenia antagonism receptor quetiapine mesolimbic pathway relieves positive symptoms antagonism receptor frontal cortex brain may relieve negative symptoms reduce severity psychotic quetiapine fewer extrapyramidal side effects less likely cause hyperprolactinemia compared drugs used treat schizophrenia used first line peak levels quetiapine occur hours plasma protein binding quetiapine major active metabolite quetiapine norquetiapine quetiapine elimination halflife metabolite norquetiapine halflife quetiapine excreted primarily via kidneys feces hepatic metabolism remainder excreted drug unmetabolized quetiapine tetracyclic compound closely related structurally clozapine olanzapine loxapine tetracyclic antipsychotics synthesis quetiapine begins dibenzothiazepinone lactam first treated phosphoryl chloride produce dibenzothiazepine nucleophilic substitution used introduce astrazeneca submitted new drug application sustainedrelease version quetiapine united states canada european union second half treatment astrazeneca retain exclusive right market sustainedrelease quetiapine sustainedrelease quetiapine marketed mainly seroquel xr marketing names seroquel prolong seroquel depot seroquel xl may astrazeneca announced us fda approved seroquel xr acute treatment earnings conference astrazeneca announced plans launch seroquel xr us august however seroquel xr become available us pharmacies fda approved seroquel xr use maintenance treatment schizophrenia addition acute treatment illness november company provided reason delay seroquel xrs launch health canada approved sale seroquel xr september early october fda approved seroquel xr treatment bipolar depression bipolar mania according astrazeneca seroquel xr first medication approved fda oncedaily acute treatment depressive manic episodes associated bipolar july handa pharmaceuticals based fremont california announced abbreviated new drug application anda quetiapine fumarate extendedrelease tablets generic version astrazenecas seroquel xr accepted fda december biovail announced fda accepted companys anda market version sustainedrelease biovails sustainedrelease tablets compete astrazenecas seroquel xr december astrazeneca notified shareholders fda asked additional information companys application expand use sustainedrelease quetiapine treatment united states food drug administration fda approved quetiapine treatment schizophrenia acute manic episodes associated bipolar disorder bipolar mania treatment bipolar quetiapine xr approved adjunctive treatment major depressive quetiapine received initial indication us fda treatment schizophrenia received second indication treatment maniaassociated bipolar studies conducted quetiapines efficacy treating generalized anxiety disorder major depression patent protection product ended however number regions longacting version remained patent april u department justice fined astrazeneca million companys aggressive marketing seroquel offlabel according department justice company recruited doctors serve authors articles ghostwritten medical literature companies studies doctors question conduct astrazeneca used studies articles basis promotional messages unapproved uses multiple lawsuits filed relation quetiapines sideeffects particular approximately filed astrazeneca alleging quetiapine caused problems ranging slurred speech chronic insomnia deaths young man named dan markingson committed suicide controversial seroquel clinical trial university minnesota involuntary commitment group university minnesota bioethicists charged trial involved alarming number ethical august uks medicines healthcare products regulatory agency mhra issued drug alert following reports batches nurofen plus contained seroquel xl tablets following issue drug alert reckitt benckiser uk ltd received reports rogue blister strips cartons two additional batches nurofen plus tablets one new batches contained seroquel xl mg tablets one contained pfizer product neurontin mg capsules following discussions mhras defective medicines report centre dmrc reckitt benckiser uk ltd decided recall remaining unexpired stock nurofen plus tablets pack size leading drug contamination later traced instore tampering httpsenwikipediaorgwikiquetiapine